Jump to:
Fusion Antibodies PLC Fundamentals
| Company Name | Fusion Antibodies PLC | Last Updated | 2025-04-17 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| Shares in Issue | 104.902 m | Market Cap | £6.82 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.04 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0.0209 | Debt Equity Ratio | 0.0085 |
|---|
| Asset Equity Ratio | 1.4429 | Cash Equity Ratio | 0.4145 |
|---|
| Quick Ratio | 2.7295 | Current Ratio | 3.25 |
|---|
| Price To Book Value | 6.4392 | ROCE | 0 |
|---|
Fusion Antibodies PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Fusion Antibodies PLC Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|
| Tangible Assets | £158,000.00 | £375,000.00 | £633,000.00 |
| Intangible Assets | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £158,000.00 | £375,000.00 | £633,000.00 |
| Stocks | £460,000.00 | £539,000.00 | £585,000.00 |
| Debtors | £557,000.00 | £690,000.00 | £1.52 m |
| Cash & Equivalents | £1.20 m | £195,000.00 | £2.05 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £2.42 m | £2.06 m | £4.92 m |
| Liabilities | 2024 | 2023 | 2022 |
|---|
| Creditors within 1 year | £584,000.00 | £879,000.00 | £1.21 m |
| Creditors after 1 year | £43,000.00 | £60,000.00 | £23,000.00 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £627,000.00 | £939,000.00 | £1.23 m |
| Net assets | £1.79 m | £1.12 m | £3.68 m |
| Equity | 2024 | 2023 | 2022 |
|---|
| Called up share capital | £3.81 m | £1.04 m | £1.04 m |
| Share Premium | £7.74 m | £7.65 m | £7.65 m |
| Profit / Loss | -£2.29 m | -£2.86 m | -£1.33 m |
| Other Equity | £1.79 m | £1.12 m | £3.68 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £1.79 m | £1.12 m | £3.68 m |
| Ratios | 2024 | 2023 | 2022 |
|---|
| Debt Ratio | £0.01 | £0.03 | £0.00 |
| Debt-to-Equity | £0.01 | £0.04 | £0.00 |
| Assets / Equity | 1.4429 | 1.4429 | 1.4429 |
| Cash / Equity | 0.4145 | 0.4145 | 0.4145 |
| EPS | -£0.04 | -£0.10 | -£0.05 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|
| Cash from operating activities | -£1.77 m | -£1.75 m | -£330,000.00 |
| Cashflow before financing | £1.00 m | -£1.75 m | -£385,000.00 |
| Increase in Cash | £1.00 m | -£1.86 m | -£642,000.00 |
| Income | 2024 | 2023 | 2022 |
|---|
| Turnover | £1.14 m | £2.90 m | £4.80 m |
| Cost of sales | £1.18 m | £2.33 m | £2.33 m |
| Gross Profit | -£45,000.00 | £574,000.00 | £2.47 m |
| Operating Profit | -£2.29 m | -£2.86 m | -£1.32 m |
| Pre-Tax profit | -£2.29 m | -£2.86 m | -£1.33 m |
Fusion Antibodies PLC Company Background
| Sector | Healthcare |
|---|
| Activities | Fusion Antibodies PLC offers various antibody engineering services for all therapeutic and diagnostic antibody development stages. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America. |
|---|
| Latest Interim Date | 19 Nov 2024 |
|---|
| Latest Fiscal Year End Date | 5 Sep 2024 |
|---|
Fusion Antibodies PLC Directors
| Appointed | Name | Position |
|---|
| 2024-10-22 | Mr. Colin James Walsh | Non-Executive Director |
| 2022-09-01 | Mr. Timothy William Watts | Non-Executive Director |
| 2024-10-22 | Dr. Simon Gordon Douglas | Non-Executive Director,Chairman |
| 2021-02-16 | Dr. Paul Gerard Kerr | Executive Director,Chief Executive Officer |
| 2023-08-24 | Mr. James Alexander Fair | Executive Director,Chief Financial Officer and Company Secretary |
| 2024-09-12 | Dr. Richard John Buick | Executive Director,Chief Technical Officer |
| 2023-12-04 | Ms. Sonya Maria Ferguson | Non-Executive Director,Senior Independent Director |
| 2022-03-31 | Dr. Alan Mawson | Non-Executive Director |
| 2022-03-14 | Dr. Richard Anthony Jones | Executive Director,Chief Executive Officer |
| 2024-10-22 | Mr. Matthew Paul Baker | Non-Executive Director |
| 2024-10-16 | Dr. Adrian Robert Kinkaid | Executive Director,Chief Executive Officer |
Fusion Antibodies PLC Contact Details
Fusion Antibodies PLC Advisors
